On a mission to rapidly and continually deliver new antibody-based therapies that keep pace with the evolving viral threats
Invivyd receives emergency use authorization from U.S. FDA
Invivyd is on a mission to rapidly and perpetually deliver antibody-based therapies that protect vulnerable people from the devastating consequences of circulating viral threats, beginning with SARS-CoV-2. This vulnerable population includes, among others, people who have a weakened immune system and may not generate adequate protection from vaccination, such as those who are immunocompromised.
OUR INVYMAB™ PLATFORM
Leveraging state-of-the-art viral surveillance, predictive modeling, and advanced antibody engineering techniques, we are taking a platform-based approach to the continuous discovery and optimization of monoclonal antibody candidates designed to protect the vulnerable from serious viral threats.
More
Our Pipeline
We are generating a robust pipeline of monoclonal antibody candidates, which could be used in prevention or treatment of serious viral diseases, starting with COVID-19 and expanding into influenza and other high-need indications.
MoreLatest Press Releases
Invivyd Announces $20 Million to $25 Million Improvement in Projected 2024 Year-End Cash Position
Join Our Team
We are united by a shared commitment to protecting the most vulnerable people in our communities from today’s and tomorrow’s serious viral threats. To keep pace with viral evolution, we have created a culture that embraces change, nimble decision making, and the relentless pursuit of our mission.
More